Search Results

An in-depth analysis of Ireland's €93.8 billion pharmaceutical and medical exports to non-EU markets. Examining trade data across the United States, UK, Switzerland, and Asia-Pacific, key manufacturing clusters in Cork, Dublin, and Limerick, and the strategic outlook for 2026.

As direct-to-patient dispensing platforms like LillyDirect expand across the UK and digital healthcare alters prescription delivery, community pharmacists in Ireland and Great Britain are adapting. This critical analysis examines the impact of mail-order platforms, recent regulatory shifts in Ireland, and how local chemists are pivoting to clinical primary care services.

An in-depth clinical and market analysis of GLP-1 therapeutics in 2026, examining central brain reward circuit mapping from the University of Virginia, Phase 3 oral small-molecule data for Orforglipron, Retatrutide triple-agonist efficacy, and systemic cardiometabolic benefits.

An in-depth commercial analysis of the UK-India Comprehensive Economic and Trade Agreement (CETA), exploring its transformative impact on bilateral pharmaceutical manufacturing, active pharmaceutical ingredient (API) supply chains, and consumer medicine pricing.

As the Turnberry Deal’s 15% tariff baseline takes hold, Brussels has formally requested carve-outs for €150 billion worth of European goods. The stakes are exceptionally high for Ireland’s €13B medical technology industry, where critical components face severe transatlantic margin pressures.

Jefferies has revised its debut-quarter US sales estimate for Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) down to $71 million - well below the Wall Street consensus of $130 million and sharply below its own prior estimate of $85 million. With weekly prescriptions hovering around 20,000 and Novo Nordisk's oral Wegovy outpacing it on trajectory, the first oral non-peptide GLP-1 for obesity is generating a very different story than the hype suggested.

The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines - a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.

Global research pipelines and venture capital inflows are concentrating in targeted cancer therapy with ADCs and next-generation cardiometabolic GLP-1 oral weight-loss compounds.

Northern Ireland-based Galen has received an expanded UK license for its emergency pain relief inhaler, Penthrox (methoxyflurane). The self-administered "green whistle" is now officially approved for use in conscious children aged six and older suffering from trauma-associated pain.

Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.

Enterprise Ireland has announced record total exports of €38.86 billion. With the Advanced Manufacturing and Life Sciences sector surging by 14% to €13.16 billion, we analyse what this means for Ireland's homegrown pharma ecosystem.

The Health Service Executive (HSE) is facing intense budgetary pressure as clinical demand for GLP-1 obesity medications skyrockets. We break down the restrictive funding, the "dreadful dichotomy" of access, and the surge in illegal online sales.

Discover the top 5 high-growth Irish life science, biotech, and medtech companies transforming the healthcare landscape. From Enterprise Ireland backed startups to global scale-ups, these are the emerging leaders of 2026.